Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib plus irinotecan versus placebo plus irinotecan in relapsed advanced esophagogastric adenocarcinoma
2015-000897-36Phase 3Completed
- Sponsor
- AB Science
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastroesophageal junction adenocarcinoma and gastric adenocarcinoma comparing Masitinib + irinotecan with Placebo + irinotecan (2 arms). Primary endpoint: Overall survival. Started Feb 2016; status: completed.
02
Drugs
masitinibirinotecan
03
Conditions
gastroesophageal junction adenocarcinomagastric adenocarcinoma
Beyond the preview
Go deeper on 2015-000897-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000897-36.